AACR 2023 – Hippo makes a splash
Vivace Therapeutics clinically validates a new mechanism, though its rival Ikena reckons more specificity is needed to avoid toxicity.
AACR 2023 – Moderna's immunotherapeutic splash
This year’s AACR meeting promises a surprising amount of clinical data relevant to biopharma investors.
Regulatory developments over the Christmas period
The FDA and Biogen come in for fierce Congressional criticism, and a handful of new cancer drugs are approved in Japan.
Kinnate is the latest Raf player to trip up
The company’s attempt to segment Braf-mutant cancers further isn’t going smoothly.
Esmo 2022 movers – Kras backfires
Inhibition of Kras dominated Esmo, though probably not in the way some had hoped.
Esmo 2022 – Springworks aims to Defi expectations
Data in the desmoid tumour niche look strong, but Ayala might provide a cheaper way for investors to play in gamma secretase inhibition.
Asco 2022 movers – cell therapy wins, but it’s not the whole story
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.